In order to study whether FGFR1 signaling promotes the generation of CD117-positive leukemia cells, MA-WT and MA-KO cells were treated with FGFR1 inhibitor (PD173074, PD17), AKT inhibitor (LY294002, LY), and MEK inhibitor (PD98059, PD98), respectively. Here, MAP2K7 is linked to leukemia.